Metropolitan Life Insurance CO Century Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jun 14, 2023	BUY	$4.84 - $11.58 $6,901 - $16,513	1,426 New	1,426 $7.32 Million
Q3 2022 Jun 14, 2023	BUY	$8.57 - $13.1 $12,220 - $18,680	1,426 New	1,426 $14.1 Million
Q2 2022 Jun 20, 2023	BUY	$7.96 - $12.43 $11,350 - $17,725	1,426 New	1,426 $11,000
Q1 2022 Jun 20, 2023	BUY	$11.62 - $15.92 $16,570 - $22,701	1,426 New	1,426 $17,000
Q1 2022 Mar 30, 2023	SELL	$11.62 - $15.92 $26,853 - $36,791	-2,311 Reduced 61.84%	1,426 $17,000
Q1 2022 May 12, 2022	BUY	$11.62 - $15.92 $16,570 - $22,701	1,426 New	1,426 $18,000
Q4 2021 Feb 15, 2022	SELL	$13.93 - $23.62 $52,056 - $88,267	-3,737 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$20.8 - $31.93 $77,729 - $119,322	3,737 New	3,737 $94,000
Q3 2021 Mar 30, 2023	BUY	$20.8 - $31.93 $48,068 - $73,790	2,311 Added 162.06%	3,737 $94,000
Q3 2021 Nov 15, 2021	BUY	$20.8 - $31.93 $77,729 - $119,322	3,737 New	3,737 $94,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $61.8M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.